Overview Dividends

(IVZ) Invesco - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: BMG491BT1088

ETF, Mutual Fund, Portfolio Management, Separate Account

Asset Management & Custody Banks
Market Cap in USD: 11,613m

IPO / Inception: 1995-08-24
Return 12m vs S&P 500: 43.0%

EPS (Earnings per Share)

EPS CAGR: -8.75%
EPS Trend: -10.0%

Last SUE: 3.09
Qual. Beats: 1

Revenue

Rev. CAGR: -1.91%
Rev. Trend: -6.0%

Last SUE: 0.88
Qual. Beats: 1

Dividends

Dividend Yield	3.09%
Yield on Cost 5y	5.91%
Yield CAGR 5y	1.27%
Payout Consistency	90.6%
Payout Ratio	43.3%

Risk via 5d forecast
Volatility	32.6%
Value at Risk 5%th	50.7%
Relative Tail Risk	-5.39%

Reward TTM
Sharpe Ratio	1.38
Alpha	39.54
CAGR/Max DD	0.53

Character TTM
Hurst Exponent	0.579
Beta	1.496
Beta Downside	1.841

Drawdowns 3y
Max DD	36.52%
Mean DD	13.51%
Median DD	14.28%

Description: IVZ Invesco November 03, 2025

Invesco Ltd. (NYSE: IVZ) is a global investment manager that serves a broad client base-including retail, institutional, high-net-worth, public entities, and sovereign wealth funds-through a suite of equity, fixed-income, multi-asset, commodity, and alternative strategies delivered via mutual funds, ETFs, and private funds.

As of the most recent filing, Invesco reported $1.6 trillion in assets under management (AUM), with a 4.2 % year-over-year growth driven largely by inflows into its active equity and ESG-focused products. The firm’s revenue mix remains heavily weighted toward fee income (≈ 85 % of total revenue), making it sensitive to fee compression trends and the ongoing shift toward low-cost passive investing. Key sector drivers include rising demand for quantitative and factor-based strategies, as well as regulatory scrutiny on fee disclosures that could affect profitability.

For a deeper quantitative view of Invesco’s valuation and risk profile, you might explore the ValueRay platform.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income (1.05b TTM) > 0 and > 6% of Revenue (6% = 376.7m TTM)

FCFTA 0.05 (>2.0%) and ΔFCFTA -0.52pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue -8.33% (prev 20.51%; Δ -28.84pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.05 (>3.0%) and CFO 1.39b > Net Income 1.05b (YES >=105%, WARN >=100%)

Net Debt (-973.1m) to EBITDA (1.52b) ratio: -0.64 <= 3.0 (WARN <= 3.5)

Current Ratio 0.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (454.6m) change vs 12m ago -0.22% (target <= -2.0% for YES)

Gross Margin 35.41% (prev 32.44%; Δ 2.97pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 22.45% (prev 21.41%; Δ 1.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio 18.85 (EBITDA TTM 1.52b / Interest Expense TTM 71.9m) >= 6 (WARN >= 3)

Altman Z'' 1.59

(A) -0.02 = (Total Current Assets 973.1m - Total Current Liabilities 1.50b) / Total Assets 28.44b

(B) 0.25 = Retained Earnings (Balance) 7.17b / Total Assets 28.44b

(D) 0.53 = Book Value of Equity 7.28b / Total Liabilities 13.65b

Total Rating: 1.59 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 69.10

1. Piotroski 6.50pt

2. FCF Yield 7.55%

3. FCF Margin 21.88%

4. Debt/Equity 0.54

5. Debt/Ebitda -0.64

6. ROIC - WACC (= 3.07)%

7. RoE 7.34%

8. Rev. Trend -6.00%

9. EPS Trend -10.02%

What is the price of IVZ shares?

As of December 21, 2025, the stock is trading at USD 27.00 with a total of 9,039,398 shares traded.
Over the past week, the price has changed by +2.82%, over one month by +17.80%, over three months by +21.11% and over the past year by +68.03%.

Is IVZ a buy, sell or hold?

Invesco has received a consensus analysts rating of 3.07. Therefor, it is recommend to hold IVZ.

Strong Buy: 1
Buy: 1
Hold: 11
Sell: 0
Strong Sell: 1

What are the forecasts/targets for the IVZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	27.1	0.3%
Analysts Target Price	27.1	0.3%
ValueRay Target Price	29.8	10.4%

IVZ Fundamental Data Overview December 17, 2025

Market Cap USD = 11.61b (11.61b USD * 1.0 USD.USD)
P/E Trailing = 17.7143
P/E Forward = 10.846
P/S = 1.8497
P/B = 1.063
P/EG = 0.478
Beta = 1.64
Revenue TTM = 6.28b USD
EBIT TTM = 1.36b USD
EBITDA TTM = 1.52b USD
Long Term Debt = 1.62b USD (from longTermDebt, last quarter)
Short Term Debt = 66.2m USD (from shortTermDebt, last fiscal year)
Debt = 7.55b USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -973.1m USD (from netDebt column, last quarter)
Enterprise Value = 18.19b USD (11.61b + Debt 7.55b - CCE 973.1m)
Interest Coverage Ratio = 18.85 (Ebit TTM 1.36b / Interest Expense TTM 71.9m)
FCF Yield = 7.55% (FCF TTM 1.37b / Enterprise Value 18.19b)
FCF Margin = 21.88% (FCF TTM 1.37b / Revenue TTM 6.28b)
Net Margin = 16.69% (Net Income TTM 1.05b / Revenue TTM 6.28b)
Gross Margin = 35.41% ((Revenue TTM 6.28b - Cost of Revenue TTM 4.05b) / Revenue TTM)
Gross Margin QoQ = 34.17% (prev 33.28%)
Tobins Q-Ratio = 0.64 (Enterprise Value 18.19b / Total Assets 28.44b)
Interest Expense / Debt = 0.34% (Interest Expense 25.7m / Debt 7.55b)
Taxrate = -2.80% (negative due to tax credits) (-9.70m / 346.7m)
NOPAT = 1.39b (EBIT 1.36b * (1 - -2.80%)) [negative tax rate / tax credits]
Current Ratio = 0.65 (Total Current Assets 973.1m / Total Current Liabilities 1.50b)
Debt / Equity = 0.54 (Debt 7.55b / totalStockholderEquity, last quarter 14.01b)
Debt / EBITDA = -0.64 (Net Debt -973.1m / EBITDA 1.52b)
Debt / FCF = -0.71 (Net Debt -973.1m / FCF TTM 1.37b)
Total Stockholder Equity = 14.28b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.68% (Net Income 1.05b / Total Assets 28.44b)
RoE = 7.34% (Net Income TTM 1.05b / Total Stockholder Equity 14.28b)
RoCE = 8.52% (EBIT 1.36b / Capital Employed (Equity 14.28b + L.T.Debt 1.62b))
RoIC = 10.20% (NOPAT 1.39b / Invested Capital 13.67b)
WACC = 7.13% (E(11.61b)/V(19.16b) * Re(11.53%) + D(7.55b)/V(19.16b) * Rd(0.34%) * (1-Tc(-0.03)))
Discount Rate = 11.53% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.17%
[DCF Debug] Terminal Value 70.95% ; FCFE base≈1.41b ; Y1≈1.74b ; Y5≈2.97b
Fair Price DCF = 65.88 (DCF Value 29.32b / Shares Outstanding 445.1m; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: -10.02 | EPS CAGR: -8.75% | SUE: 3.09 | # QB: 1
Revenue Correlation: -6.00 | Revenue CAGR: -1.91% | SUE: 0.88 | # QB: 1
EPS next Quarter (2026-03-31): EPS=0.56 | Chg30d=+0.004 | Revisions Net=+0 | Analysts=7
EPS next Year (2026-12-31): EPS=2.51 | Chg30d=-0.010 | Revisions Net=+1 | Growth EPS=+26.7% | Growth Revenue=+14.6%

Additional Sources for IVZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle